Accéder au contenu
Merck

Clinical results of topography-based customized ablations in highly aberrated eyes and keratoconus/ectasia with cross-linking.

Journal of refractive surgery (Thorofare, N.J. : 1995) (2013-03-02)
David T C Lin, Simon Holland, Johnson C H Tan, Gregory Moloney
RÉSUMÉ

To report results of a series of highly aberrated corneas treated with a topography-guided excimer laser ablation. Retrospective, nonrandomized, consecutive series of eyes treated with topography-guided photorefractive keratectomy (TG-PRK) with the customized topographical neutralization technique (TNT). Cases included postoperative refractive surgery decentered ablations, optical zone enlargement, asymmetrical astigmatism, postoperative radial keratotomy (RK), postoperative keratoplasty, keratoconus combined with collagen cross-linking (CXL), and postoperative LASIK ectasia combined with CXL. Uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), and manifest refraction were analyzed preoperatively and 6 months postoperatively. In decentered ablation cases, 94% of 37 eyes were within 1.00 diopter (D) of the attempted refractive outcome, with 76% within 0.50 D. Mean topographic, central, optical zone of uniform (monodioptric) power increased from 3.5 to 5.2 mm in 25 eyes. Thirty-one eyes treated for asymmetrical astigmatism showed improvement in cylinder from mean 1.31 to 0.52 D. Ten of 11 eyes treated for previous RK astigmatism achieved postoperative UDVA 20/40 or better. Twenty-seven eyes with postoperative keratoplasty astigmatism were treated, with 7 (25.9%) eyes gaining > or = 2 lines and 12 (44.4%) eyes gaining > or = 1 line of CDVA. Of eyes with keratoconus that were treated using TG-PRK with CXL, 42 (58%) eyes had UDVA 20/40 or better, and 66 (92%) eyes had CDVA 20/40 or better. Twelve (71%) of 17 eyes treated for postoperative LASIK ectasia using TG-PRK with CXL had UDVA 20/40 or better. Nine (53%) eyes gained > or = 2 lines of CDVA. Topography-guided laser treatment with custom TNT, combined with CXL in keratoconus and ectasia, is an effective, safe, and increasingly predictable option for highly aberrated corneas.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
(−)-Riboflavine, from Eremothecium ashbyii, ≥98%
Sigma-Aldrich
(−)-Riboflavine, BioReagent, suitable for cell culture, suitable for insect cell culture, ≥98%
Supelco
Riboflavin (B2), analytical standard
Supelco
(−)-Riboflavine, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
(−)-Riboflavine, meets USP testing specifications
(−)-Riboflavine, European Pharmacopoeia (EP) Reference Standard